Work

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.380.380

Authors: Stephan A. Grupp, Shannon L Maude, Pamela Shaw, Richard Aplenc, David M. Barrett, Colleen Callahan, Anne Chew, Simon F. Lacey, Bruce L. Levine, J. Joseph Melenhorst, Laura Motley, Susan R. Rheingold, Angela Shen, David T. Teachey, Patricia A. Wood, David L Porter, Carl H. June

Institutions: Children's Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W996750591

FWCI: 2.162

Cites:

Cited by: 23

Related to: 10